Home  /  Resource Library  /  Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

ASH 2019: Results of a study examining the combination of bendamustine and rituximab for first line treatment of mantle cell lymphoma.